• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.95
  • VXN 18.04
  • VXO -
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. The company?s principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson?s disease. Teva Pharmaceutical also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler; Spiromax/Airmax, a multidose dry powder inhaler; Steri-Nebs, the blow-fill-seal based nebulizers; and Cyclohaler, a single dose dry powder device. The company?s branded respiratory products include ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm; and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma. In addition, it offers APIs for respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company provides women?s health care products, such as oral contraceptives, intrauterine contraception, and hormone therapy treatments for menopause/perimenopause, as well as therapies for use in infertility and urinary incontinence. It also holds a biotechnology platform focused on the development of peptide and protein-based medicines. Teva Pharmaceutical has cooperation agreements with Kowa Company, Ltd.; Lonza Group Ltd.; H. Lundbeck A/S; Impax Laboratories, Inc.; Anchen Pharmaceuticals, Inc.; sanofi-aventis; and OncoGenex Pharmaceuticals. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

TEVA (Teva Pharmaceutical Industries Limited American Depositary Shares)
Last Trade 7.73 Date 9/19/2019
Change % -0.77 % Price Change -0.06
Open 7.82 52 Week High 0.0
High 7.85 52 Week Low 0.0
Low 7.71 Type stock
Volume 1405154 Average Volume 0
Prev Close 7.79 Stock Exchange NYSE
Bid 7.72 Ask 7.73
Bid Size 52 Ask Size 25
1st Yr Estimated EPS Growth 0.5276 2nd Yr Estimated EPS Growth 0.0917
2 Years Forward Earning Yield 0.3552 2 Years Forward PE Ratio 2.8153
2 Years EV/Forward EBIT 8.0059 2 Years EV/Forward EBITDA 6.9881
Book Value per Share 12.9333 Book Value Yield 1.6602
Buy Back Yield CAPE Ratio
Cash Return 0.0024 Cash Flow per Share 0.6364
Cash Flow Yield 0.0817 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.4981 EV/EBIT
EV/EBITDA EV / Free Cash Flow 423.4629
EV / Forward EBIT 8.9993 EV / Forward EBITDA 7.4538
EV / Forward Revenue 2.0526 EV / Pre Tax Income
EV / Revenue 2.0074 EV / Total Asset 0.5986
Expected Dividend Growth Rate Free Cash Flow per Share 0.0794
Free Caash Flow Ratio 98.070536 Free Cash Flow Yield 0.0102
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield 0.3254 Forward PE Ratio 3.0731
Forward Return on Asset 0.0466 Forward Return on Equity 0.196
Normalized PE Ratio 3.245833 Payout Ratio 0.0
PB Ratio 0.602319 PB Ratio 10 Year Growth -0.134215
PB Ratio 3 Year Growth 1.10515 Cash Ratio 3 Year Average 1846.6544
Price to Cash Flow Ratio 12.240602 PEG Payback 1.9646
PEG Ratio 0.8307 PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg 552.155082
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth 0.182384
Free Cash Flow Ratio 3 Year Avg 11.907991 Price Change 1 Month 1.128986
Price to Cash Ratio 3.928845 Price / EBITDA
Price to Sales Ratio 0.464894 Price to Sales Ratio 10 Year Growth -0.185133
Price to Sales Ratio 3 Year Avg 1.047894 Price to Sales Ratio 5 Year Avg
Sale per Share 16.7565 Sales Yield 2.151
Sustainable Growth Rate -0.2832 Tangible Book Value per Share -21.2711
Tangible Book Value per Share 3 year Avg -31.8319 Tangible Book Value per Share 5 year Avg -20.3298
Total Asset per Share 54.4223 Total Yield
Working Capital per Share -0.5925 Working Capital per Share 3 Year Avg -1.1494
Working Capital per Share 5 Year Avg -0.266 Beta 2.425953